Sharply Shrinking RevenueVery steep revenue decline undermines scale economics and long-term viability. Persistent top-line contraction erodes the base needed to cover fixed costs, impairs R&D or product investment, and makes margin recovery and debt servicing harder, worsening solvency risk over a multi-month horizon.
Negative Gross ProfitCosts exceeding sales at the gross-profit level means the core business is not covering direct costs, not just overhead. Negative gross profit is structurally damaging: it requires either sustained cost reduction or higher pricing/volume to restore unit economics, a difficult multi-month challenge in specialty/generic drugs.
Stressed Balance Sheet And Negative EquityNegative equity and a recent meaningful debt increase create acute solvency and refinancing risk. With minimal tangible assets reported, the company faces limited collateral and tightening financing options, increasing dilution or distress likelihood and constraining strategic choices over the coming months.